Merck & Company, Inc. Press Releases

MRK 
$57.8001
*  
0.0201
0.03%
Get MRK Alerts
*Delayed - data as of Dec. 29, 2014 9:47 ET  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    MRK Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award
12/22/2014 8:00:00 AM - GlobeNewswire


Merck Begins Tender Offer to Acquire Cubist
12/19/2014 8:00:00 AM - Business Wire
▼-2.03 % Price Change since this news event. The Volume Ratio is 1.63.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers
12/18/2014 7:30:00 AM - Business Wire
▼-0.34 % Price Change since this news event. The Volume Ratio is 1.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST
12/12/2014 8:30:00 PM - PR Newswire


CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
12/11/2014 2:22:00 PM - Business Wire


Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health
12/10/2014 9:30:00 AM - Business Wire
▼-3.34 % Price Change since this news event. The Volume Ratio is 1.29.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer
12/10/2014 8:45:00 AM - Business Wire
▼-3.97 % Price Change since this news event. The Volume Ratio is 1.28.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium
12/10/2014 8:30:00 AM - Business Wire
▼-3.65 % Price Change since this news event. The Volume Ratio is 1.28.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ryan & Maniskas, LLP Announces Investigation of Cubist Pharmaceuticals Inc.
12/9/2014 10:53:00 AM - PR Newswire


Merck Statement Regarding CUBICIN Patent Litigation
12/9/2014 8:11:00 AM - Business Wire
▼-4.38 % Price Change since this news event. The Volume Ratio is 2.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Harwood Feffer LLP Announces Investigation of Cubist Pharmaceuticals Inc.
12/8/2014 8:00:00 PM - PR Newswire


CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
12/8/2014 10:45:00 AM - PR Newswire


CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
12/8/2014 10:45:00 AM - PR Newswire


Block & Leviton LLP Investigates Cubist Pharmaceuticals Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Proposed Acquisition by Merck & Co.
12/8/2014 10:32:00 AM - PR Newswire


Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
12/8/2014 7:00:00 AM - Business Wire
▼-6.18 % Price Change since this news event. The Volume Ratio is 1.54.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting
12/6/2014 1:00:00 PM - Business Wire
▼-6.18 % Price Change since this news event. The Volume Ratio is 1.5.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck's HIV Education Campaign, I Design, Reveals Video and Poem Created by the HIV Community in Honor of World AIDS Day
12/1/2014 8:00:00 AM - PR Newswire
▼-4.24 % Price Change since this news event. The Volume Ratio is 1.22.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Increased Quarterly Dividend
11/25/2014 1:00:00 PM - Business Wire


Papa John’s Accelerates International Growth in India
11/24/2014 8:30:00 PM - Business Wire


InvestorsObserver releases comments on Merck, Hewlett-Packard, Campbell Soup, Tiffany & Co., and Chico's Fas
11/24/2014 9:31:00 AM - PR Newswire


Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
11/24/2014 8:00:00 AM - Business Wire


Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
11/24/2014 7:30:00 AM - GlobeNewswire


Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Ireland For The Treatment Of Chronic Diabetic Macular Edema
11/17/2014 11:45:00 AM - PR Newswire


VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
11/17/2014 11:45:00 AM - Business Wire


Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today
11/17/2014 8:30:00 AM - Business Wire